Priors rates this Uncertain — 50 out of 100, updated weekly. It is genuinely uncertain. On the claim that in people with type 2 diabetes and chronic kidney disease (eGFR ≥20 mL/min/1.73m² and urinary albumin-to-creatinine ratio ≥200 mg/g), SGLT2 inhibitors should be used to reduce CKD progression regardless of HbA1c target, its four-agent AI review panel weighs 15 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Type 2 Diabetes Management review.